Donanemab is an amyloid beta-directed antibody used to treat Alzheimer’s disease. On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.
- Mechanism
- Curator reviewed · 8 references
The accumulation of amyloid plaques, which are made up of beta (β)-amyloid peptides, and neurofibrillary tangles, which contain hyperphosphorylated tau proteins, are common pathophysiological features of AD. It is believed that these features contribute to synaptic dysfunction and cognitive impairment in AD.
Donanemab is a monoclonal antibody targeted against the insoluble, modified, N-terminal truncated form of the β-amyloid present only in brain amyloid plaques called pyroglutamate amyloid beta (Aβ). Upon binding to pyroglutamate Aβ at position 3 (pGlu3-Aβ, AβpE3), donanemab promotes plaque removal through microglial-mediated phagocytosis.
- Primary indication
- Donanemab is indicated for the treatment of Alzheimer’s disease.Curator reviewed · 2 structured indications
- Formula / weight
- C6452H10038N1708O2013S42 · 145000.0 Da
- First approval
- Canada, 2026 · United States, 2024 · European Union, 2025
- Also known as
- IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (VH (HOMO SAPIENS IGHV1-3*01 (84.7%)-(IGHD)-IGHJ4*01 ( · Immunoglobulin G1, anti-(human pyroglutamyl Aβ (3-x) peptide)(human clone LY3002813 γ1-chain), disulfide with human clone LY3002813 κ-chain, dimer
- Code names
- LY-3002813
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Donanemab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account